The small molecule drug developer, co-founded by a UCLA associate professor, has completed its series B round.
Octant Bio, a US-based small molecule therapeutics developer co-founded by Sri Kosuri, an associate professor at University of California, Los Angeles (UCLA), has secured $80m in its series B round.
Life sciences investment firm Catalio Capital Management led the round, which also featured pharmaceutical firm Bristol Myers Squibb (BMS), boutique investment bank Allen & Company and venture capital firms 50 Years VC and Andreessen Horowitz, the latter through its Bio Fund.
Octant has developed a drug development technology platform that combines…
